SIMULECT basiliximab Inj

Simulect (basiliximab) is a chimeric monoclonal antibody produced by recombinant DNA technology, which functions as an immunosuppressant, specifically binding to and blocking the interleukin-2 receptor α – chain (IL-2R α, also known as CD25 antigen) on the surface of activated T- lymphocytes.

Manufacturer : Novartis

Strengths available :  10mg & 20mg

Storage : Store at temperature between 2°C to 8°C

Dosage :

Adult Dose

The adult dose of Simulect is 40 mg, given as two 20 mg doses, by intravenous injection. The first 20 mg dose is given within 2 hours prior to transplantation surgery. Simulect must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression. The second 20 mg dose is given 4 days after transplantation. The second dose should be withheld if severe hypersensitivity reactions to Simulect or post-operative complications such as graft loss occur (see “PRECAUTIONS”).

 Paediatric Dose 

In paediatric patients weighing less than 35 kg, the recommended total dose of Simulect is 20 mg, given in two doses of 10 mg each. In paediatric patients weighing 35 kg or more, the recommended dose is the adult dose, i.e. a total dose of 40 mg, given in two doses of 20 mg each. The first dose is given within 2 hours prior to transplantation surgery. Simulect must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression. The second dose is given 4 days after transplantation. The second dose should be withheld if severe hypersensitivity reactions to Simulect or postoperative complications such as graft loss occur (see “PRECAUTIONS”).  

Common Side effects are pain or burning when you urinate, easy bruising or bleeding, unusual weakness, tremors, shaking, fever, chills, body aches, flu symptoms, vomiting, diarrhea, trouble breathing, pale skin, feeling light-headed or short of breath, rapid heart rate.

Pack of 1 vial